gilead_advert_US_ad_temps 09/10/2009 10:12 Page 7
WHEN IT COMES TO PULMONARY ARTERIAL HYPERTENSION (PAH)
It starts with a proper diagnosis
Tranststhoraracic Doppler ecr echooccaardiooggraa phy
ScreenScreen
1
is ts the me moosst ct commonlly uy useed scd screening
tooool flffoorPr PPAAH
Excludeclude
2
Appprprooprpriaiate ddiaiagnososttiic ttessttiingg ca cann
ddiistiinguinguishshP PPAAH frH froomm o othther dr diiseaasseess
DiDiagagnonossee
1
RiRight ht heeart ct caatheetterization is rs requireedd
to confirm a diagnosis of PPAAH
Functional stal status (WHO cHO class and
Evaluatvaluate
1
6-minutee w walkk d distastance) reflecflects disesease
sseeverity ay and is ps prognosstticallly iy imppoortant
MMaanagege
3
Collaboration wn wiithPh PPAAH centers cs caan
have a se a subsstatantial imppaact ot on on outcomes
GILEAD SCIENCESSCIENCES , INCI NC. ISI S DEDICDEDICATED TO HELPINGHELPING
PHYSICIANSS ICIANS RECRECOGNIZE, DIADIAGNOSEGNOS E , ANDAND MM ANAGE PPAAHH .
References: 1. McGoon M, Gutterman D, SteenVV,, et al. Screening, early detection, and diagnosis of pulmonary arterial
hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126(1, suppl):14S-34S. 2. Lee SH, Rubin LJ.
Current treatment strategies for pulmonary arterial hypertension. J Intern Med. 2005;258(3):199-215. 3. Rubin LJ, Badesch DB.
Evaluation and management of the patient with pulmonary arterial hypertension. Ann Intern Med. 2005;143(4):282-292.
© 2009 Gilead Sciences, Inc. All rights reserved. ABS3197 February 2009
Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc.